These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39001731)

  • 21. Prognostic value of right ventricular systolic function in cardiac amyloidosis.
    Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T
    Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
    Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
    Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
    Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-Florbetapir and 18F-FDG PET/CT in Systemic Immunoglobulin Light Chain Amyloidosis Involving the Peripheral Nerves.
    Broski SM; Spinner RJ; Howe BM; Dispenzieri A; Johnson GB
    Clin Nucl Med; 2016 Feb; 41(2):e115-7. PubMed ID: 26284768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using
    Nodoushani A; El-Sady MS; Park MA; Castilloveitia GL; Falk RH; Di Carli MF; Kijewski MF; Dorbala S
    J Nucl Cardiol; 2021 Oct; 28(5):2004-2010. PubMed ID: 31758410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis.
    Arenja N; Andre F; Riffel JH; Siepen FAD; Hegenbart U; Schönland S; Kristen AV; Katus HA; Buss SJ
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):53. PubMed ID: 31434577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
    Briasoulis A; Bampatsias D; Petropoulos I; Rempakos A; Patras R; Theodorakakou F; Makris N; Dimopoulos MA; Stamatelopoulos K; Kastritis E
    Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):698-707. PubMed ID: 38142437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.
    Ternacle J; Bodez D; Guellich A; Audureau E; Rappeneau S; Lim P; Radu C; Guendouz S; Couetil JP; Benhaiem N; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Mohty D; Deux JF; Damy T
    JACC Cardiovasc Imaging; 2016 Feb; 9(2):126-38. PubMed ID: 26777222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.
    Knight DS; Zumbo G; Barcella W; Steeden JA; Muthurangu V; Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Kotecha T; Francis R; Rezk T; Quarta CC; Whelan CJ; Lachmann HJ; Wechalekar AD; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):823-833. PubMed ID: 29680336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Accuracy of [
    Rosengren S; Skibsted Clemmensen T; Tolbod L; Granstam SO; Eiskjær H; Wikström G; Vedin O; Kero T; Lubberink M; Harms HJ; Flachskampf FA; Baron T; Carlson K; Mikkelsen F; Antoni G; Frost Andersen N; Hvitfeldt Poulsen S; Sörensen J
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1337-1347. PubMed ID: 32417330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis.
    Lin L; Li X; Feng J; Shen KN; Tian Z; Sun J; Mao YY; Cao J; Jin ZY; Li J; Selvanayagam JB; Wang YN
    J Cardiovasc Magn Reson; 2018 Jan; 20(1):2. PubMed ID: 29298704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indexed left ventricular mass to QRS voltage ratio is associated with heart failure hospitalizations in patients with cardiac amyloidosis.
    Slivnick JA; Wallner AL; Vallakati A; Truong VT; Mazur W; Elamin MB; Tong MS; Raman SV; Zareba KM
    Int J Cardiovasc Imaging; 2021 Mar; 37(3):1043-1051. PubMed ID: 33068247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations Between Atrial Cardiopathy and Cerebral Amyloid: The ARIC-PET Study.
    Johansen MC; Mosley TH; Knopman DS; Wong DF; Ndumele C; Shah AM; Solomon SD; Gottesman RF
    J Am Heart Assoc; 2020 Dec; 9(24):e018399. PubMed ID: 33289449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
    Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
    Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary transit time is a predictor of outcomes in heart failure: a cardiovascular magnetic resonance first-pass perfusion study.
    Farley J; Brown LA; Garg P; Wahab A; Klassen JR; Jex N; Thirunavukarasu S; Chowdhary A; Sharrack N; Gorecka M; Xue H; Artis N; Levelt E; Dall'Armellina E; Kellman P; Greenwood JP; Plein S; Swoboda PP
    BMC Cardiovasc Disord; 2024 Jun; 24(1):329. PubMed ID: 38943084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis.
    Ochs MM; Fritz T; Arenja N; Riffel J; Andre F; Mereles D; Siepen FAD; Hegenbart U; Schönland S; Katus HA; Friedrich MGW; Buss SJ
    J Cardiovasc Magn Reson; 2017 Nov; 19(1):87. PubMed ID: 29121956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.